Abstracts

Factors Affecting Risk of Major Adverse Cardiovascular Events Among People With HIV in REPRIEVE

Background: People with HIV (PWH) have a 2-fold increased risk of major adverse cardiovascular events (MACE). REPRIEVE showed pitavastatin reduced MACE by 35% among PWH with low-to-moderate traditional risk. Enhanced understanding of the relative contributions of traditional and HIV-specific risk factors (RF) to MACE may guide concomitant individual- and population-level preventive interventions. Methods: Analyses in…

Performance of the ACC/AHA Pooled Cohort Equations for Risk Prediction in the Global REPRIEVE Trial

Background: People with HIV (PWH) have a higher burden of cardiovascular (CV) disease than the general population; estimating this risk is an essential component of prevention. However, it is unknown how well the 2013 ACC/AHA guideline-recommended Pooled Cohort Equation (PCE) estimates risk among PWH globally. Leveraging the international REPRIEVE Trial, which prospectively adjudicated incident CV…

Spatial Profiling Reveals Immunometabolic Pathways Involved in Trained Immunity in PWH With CVD

Background: People with HIV (PWH) are at increased risk for cardiovascular disease (CVD). Chronic exposure of innate immune cells to microbial products and pro-inflammatory lipids may drive trained immunity in these cells through transcriptomic and metabolism changes. Methods: We measured coronary artery calcium (CAC) scores among people with and without HIV (N=25,43) to assess atherosclerosis…

IL-32 Isoforms Potentially Impact Bone and Cardiovascular Diseases in HIV Infection

Background: We have recently demonstrated that the multi-isoform proinflammatory cytokine IL-32 is upregulated by HIV infection and is associated with subclinical CVD in people living with HIV (PLWH). However, mechanisms by which IL-32 isoforms contribute to the pathogenesis of CVD and potentially other chronic diseases like osteoporosis remain unclear. We investigated the impact of IL-32…

Endothelial Dysfunction in HIV: Exploring Cytokine and Chemokine Dynamics

Background: In persons living with HIV (PWH), chronic inflammation promotes endothelial dysfunction, which contributes to cardiovascular disease. In this study, we sought to understand how subsets of endothelial cells (ECs) in adipose tissue modulate inflammation. Methods: We analyzed the expression of cytokine/chemokine receptors by ECs in the subcutaneous adipose tissue of 59 PWH using single-cell…

Endothelial Microvesicles: Circulating Biomarker and Mediator of Vascular Dysfunction With HIV-1

Background: We have previously reported that circulating endothelial cell derived extracellular microvesicles (EMVs) are elevated in adults living with HIV (ALWH) receiving antiretroviral therapy (ART) contributing to endothelial vasodilator dysfunction by negatively affecting endothelial nitric oxide synthase (eNOS) and, in turn, impairing NO production. However, whether elevations in circulating EMVs and their pathologic effects on…

Activated and Exhausted CD8+ T-Cell Subsets Associate With Carotid Atherosclerotic Plaques in PLHIV

Background: Atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes of morbidity and mortality in people living with HIV (PLHIV). Understanding the association between circulating immune cells and carotid plaque presence in PLHIV holds the potential to identify novel immunological mechanisms driving plaque progression in PLHIV. Flow cytometry, allows identification and quantification of immune…

Baseline KSHV T-Cell Responses Are Associated With Pre-Treatment Clinical Presentation in KS

Background: T cell immunity is important in controlling KS herpesvirus (KSHV) disease progression. We evaluated T cell responses to KSHV and associations with pre-treatment clinical characteristics and outcomes in 2 ACTG/AMC studies (A5263/AMC066; A5264/AMC067) of KS treatment in resource-limited settings. Methods: T cell ELISPOT responses (log10 spot-forming units [SFU]/10^6 cells) to 2 latency (LANA, K12)…